485 related articles for article (PubMed ID: 27717710)
41. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
42. Chemical probes of histone lysine methyltransferases.
Kaniskan HÜ; Jin J
ACS Chem Biol; 2015 Jan; 10(1):40-50. PubMed ID: 25423077
[TBL] [Abstract][Full Text] [Related]
43. Histone methyltransferases in cancer.
Albert M; Helin K
Semin Cell Dev Biol; 2010 Apr; 21(2):209-20. PubMed ID: 19892027
[TBL] [Abstract][Full Text] [Related]
44. Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation.
Litt M; Qiu Y; Huang S
Biosci Rep; 2009 Apr; 29(2):131-41. PubMed ID: 19220199
[TBL] [Abstract][Full Text] [Related]
45. Screening for histone codebreakers.
Bedford MT
J Biol Chem; 2018 Aug; 293(35):13766-13767. PubMed ID: 30171150
[TBL] [Abstract][Full Text] [Related]
46. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Wang Y; Hu W; Yuan Y
J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
48. Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors.
Lee DY; Northrop JP; Kuo MH; Stallcup MR
J Biol Chem; 2006 Mar; 281(13):8476-85. PubMed ID: 16461774
[TBL] [Abstract][Full Text] [Related]
49. Controllers of histone methylation-modifying enzymes in gastrointestinal cancers.
Li L; Song Q; Zhou J; Ji Q
Biomed Pharmacother; 2024 May; 174():116488. PubMed ID: 38520871
[TBL] [Abstract][Full Text] [Related]
50. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
Zhou Z; Feng Z; Hu D; Yang P; Gur M; Bahar I; Cristofanilli M; Gradishar WJ; Xie XQ; Wan Y
EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of selected histone modifier genes in human solid cancers.
Ozdağ H; Teschendorff AE; Ahmed AA; Hyland SJ; Blenkiron C; Bobrow L; Veerakumarasivam A; Burtt G; Subkhankulova T; Arends MJ; Collins VP; Bowtell D; Kouzarides T; Brenton JD; Caldas C
BMC Genomics; 2006 Apr; 7():90. PubMed ID: 16638127
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological inhibition of arginine and lysine methyltransferases induces nuclear abnormalities and suppresses angiogenesis in human endothelial cells.
Balcerczyk A; Rybaczek D; Wojtala M; Pirola L; Okabe J; El-Osta A
Biochem Pharmacol; 2016 Dec; 121():18-32. PubMed ID: 27659811
[TBL] [Abstract][Full Text] [Related]
53. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1.
Rezai-Zadeh N; Zhang X; Namour F; Fejer G; Wen YD; Yao YL; Gyory I; Wright K; Seto E
Genes Dev; 2003 Apr; 17(8):1019-29. PubMed ID: 12704081
[TBL] [Abstract][Full Text] [Related]
54. Histone methyltransferase activity affects metabolism in human cells independently of transcriptional regulation.
Perez MF; Sarkies P
PLoS Biol; 2023 Oct; 21(10):e3002354. PubMed ID: 37883365
[TBL] [Abstract][Full Text] [Related]
55. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
56. Interaction between DNA/histone methyltransferases and their inhibitors.
Hu J; Chen S; Kong X; Zhu K; Cheng S; Zheng M; Jiang H; Luo C
Curr Med Chem; 2015; 22(3):360-72. PubMed ID: 25386815
[TBL] [Abstract][Full Text] [Related]
57. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
58. Endothelial transcriptome in response to pharmacological methyltransferase inhibition.
Okabe J; Fernandez AZ; Ziemann M; Keating ST; Balcerczyk A; El-Osta A
ChemMedChem; 2014 Aug; 9(8):1755-62. PubMed ID: 24850797
[TBL] [Abstract][Full Text] [Related]
59. Design and synthesis of peptide-MCA substrates for a novel assay of histone methyltransferases and their inhibitors.
Chi H; Takemoto Y; Nsiama TK; Kato T; Nishino N; Ito A; Yoshida M
Bioorg Med Chem; 2014 Feb; 22(4):1268-75. PubMed ID: 24486204
[TBL] [Abstract][Full Text] [Related]
60. Emerging epigenetic targets and therapies in cancer medicine.
Popovic R; Licht JD
Cancer Discov; 2012 May; 2(5):405-13. PubMed ID: 22588878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
